Reviewing OmniAb (OABI) and Its Peers

OmniAb (NASDAQ:OABIGet Free Report) is one of 35 publicly-traded companies in the “Commercial physical research” industry, but how does it compare to its peers? We will compare OmniAb to related businesses based on the strength of its risk, analyst recommendations, earnings, institutional ownership, valuation, profitability and dividends.

Volatility and Risk

OmniAb has a beta of -0.54, suggesting that its stock price is 154% less volatile than the S&P 500. Comparatively, OmniAb’s peers have a beta of 6.20, suggesting that their average stock price is 520% more volatile than the S&P 500.

Earnings and Valuation

This table compares OmniAb and its peers revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
OmniAb $66.12 million -$22.33 million -25.35
OmniAb Competitors $976.30 million $21.04 million 0.28

OmniAb’s peers have higher revenue and earnings than OmniAb. OmniAb is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.


This table compares OmniAb and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
OmniAb N/A -6.38% -4.33%
OmniAb Competitors -1,078.51% -120.15% -25.87%

Analyst Ratings

This is a breakdown of recent ratings and price targets for OmniAb and its peers, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
OmniAb 0 0 9 0 3.00
OmniAb Competitors 42 614 930 18 2.58

OmniAb currently has a consensus price target of $10.00, indicating a potential upside of 71.53%. As a group, “Commercial physical research” companies have a potential upside of 16.04%. Given OmniAb’s stronger consensus rating and higher probable upside, analysts plainly believe OmniAb is more favorable than its peers.

Insider & Institutional Ownership

58.7% of OmniAb shares are held by institutional investors. Comparatively, 48.6% of shares of all “Commercial physical research” companies are held by institutional investors. 7.0% of OmniAb shares are held by insiders. Comparatively, 14.6% of shares of all “Commercial physical research” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.


OmniAb beats its peers on 7 of the 13 factors compared.

OmniAb Company Profile

(Get Free Report)

OmniAb, Inc., a biotechnology company, engages in the provision of therapeutic antibody discovery technologies in the United States. The company's discovery platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTau, which features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.

Receive News & Ratings for OmniAb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OmniAb and related companies with's FREE daily email newsletter.